Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 12/20 | 0.71 |
| ▸ | NPC1 | O15118 | 3/20 | 0.67 |
| ▸ | RAB9A | P51151 | 3/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.67 |
| ▸ | MITF | O75030 | 1/20 | 0.67 |
| ▸ | XBP1 | P17861 | 1/20 | 0.67 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.67 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.67 |
| ▸ | KDR | P35968 | 4/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5284418 | 1.00 | TRPV1 (0.71) | TRPV1NPC1RAB9AKDM4EMITF | |
| SCHEMBL5909669 | 0.89 | KDR (0.65) | TRPV1NPC1RAB9AKDM4EMITF | |
| SCHEMBL5909673 | 0.89 | KDR (0.65) | TRPV1NPC1RAB9AKDM4EMITF | |
| SCHEMBL3585769 | 0.87 | KDR (0.57) | TRPV1NPC1RAB9AKDM4EMITF | |
| SCHEMBL3585763 | 0.87 | KDR (0.57) | TRPV1NPC1RAB9AKDM4EMITF | |
| SCHEMBL5909541 | 0.85 | NPC1 (0.67) | TRPV1NPC1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL5909540 | 0.85 | NPC1 (0.67) | TRPV1NPC1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL19631472 | 0.83 | KDM4E (0.67) | TRPV1NPC1RAB9AKDM4EMITF | |
| SCHEMBL846396 | 0.83 | TRPV1 (1.00) | TRPV1NPC1RAB9AKDM4EMITF | |
| SCHEMBL21356567 | 0.83 | KDR (0.67) | TRPV1NPC1RAB9AKDM4EMITF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1853269-A2 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | Renovis, Inc. (US) | 2007-11-14 | — | — | EP | claimed |
| WO-2006093832-A2 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | RENOVIS, INC. (US) | 2006-09-08 | — | — | WO | claimed |
| US-20060194801-A1 | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | EVOTEC AG (DE) | 2006-08-31 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194801-A1 | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | TRPV1, TRPA1, TRPV2 | TRPV1 1/4885NPC1 959/4885RAB9A 2274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.